Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $30 to $34.
Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $30 to $34.